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Autistic disorder: current psychopharmacological
treatments and areas of interest for future developments
Autismo: tratamentos psicofarmacológicos e áreas
de interesse para  desenvolvimentos futuros
Abst rac t
Autistic disorder and the group of related conditions defined as pervasive developmental disorders are chronic neurodevelopmental
disorders starting in early childhood and affecting a significant number of children and families. Although the causes and much
of the pathophysiology of the disorder remain unknown, in recent years a number of available medication treatments have been
identified as holding promise in alleviating some of the most disabling maladaptive behaviors, associated with pervasive developmental
disorders. However these treatments do not address the core symptoms of the disease and oftentimes their side effects outweigh
their benefits. Therefore there is substantial need for new medications that are safer and more effective in addressing the behavior
symptoms of autism. The aim of this review is to highlight the available current pharmacotherapies and those emerging treatments
with potential to enhance the treatment options of patients with pervasive developmental disorders.
Keywords: Autistic disorder; Antipsychotic agents; Anticonvulsants; Antidepressant agents; Disease management
Resumo
O transtorno autista e o grupo de condições relacionadas definidas como transtornos invasivos do desenvolvimento são transtornos
de neurodesenvolvimento crônicos que começam na infância precoce e afetam um número significativo de crianças e suas
famílias. Ainda que as causas e muito da fisiopatologia do transtorno sejam desconhecidas, em anos recentes, vários tratamentos
medicamentosos disponíveis têm sido identificados como contendo a promessa de aliviar alguns dos comportamentos mal-
adaptativos mais comprometedores associados aos transtornos invasivos do desenvolvimento. No entanto, esses tratamentos não
enfocam os sintomas nucleares da enfermidade e, geralmente, seus efeitos colaterais excedem os benefícios. Portanto, há uma
necessidade substancial de novas medicações que sejam mais seguras e mais eficazes em tratar os sintomas comportamentais do
autismo. O objetivo desta revisão é o de destacar as farmacoterapias correntes disponíveis e aquelas emergentes e que tenham
potencial de melhorar as opções de tratamento de pacientes com transtornos invasivos do desenvolvimento.
Descritores: Transtorno autístico; Agentes antipsicóticos; Anticonvulsivantes; Agentes antidepressivos;
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Int roduct ion
Autism is a neuropsychiatric disorder developing in early
childhood. It is part of a group of conditions, defined as PDDs,
often referred to also as “autistic spectrum” disorders. Common
feature of the PDDs is pervasive impairment in several areas
of functioning, namely social interaction, communication and
the presence of repetitive behaviours and restricted interests.
These deficits develop relative to the individual’s mental age
and usually become evident by the 3
rd
 year of life. Often they
are accompanied by some degree of mental retardation. There
are several types of PDD defined in the Diagnostic and
Statistical Manual Fourth Edition of the American Psychiatric
Association.
1
 They include autistic disorder, Rett’s disorder,
childhood disintegrative disorder, Asperger’s disorder and PDD
- Not Otherwise Specified (PDD-NOS). In the International
Classification of Diseases-10,
2
 these are given similar, though
not identical labels. ICD-10 includes also two other categories,
Atypical Autism and Overactive Disorder Associated with Men-
tal Retardation and Stereotyped Movements.
Autistic disorder by definition begins prior to the age of 3
years.
1
 The diagnosis requires presence of disturbance in three
domains: 1) social interaction; 2) communication; 3) restricted
interests and stereotyped patterns of behavior. The social deficits
manifest themselves as lack of spontaneous interest in sharing
enjoyment, failure to use non-verbal means of communication
(body language, gestures, facial expression, eye contact) to
regulate social interactions, and failure to develop peer
relationships appropriate for age and developmental level. The
communication disturbance is evidenced by lack of spoken
language, or delayed and deviant language. There may be
stereotyped, repetitive, or idiosyncratic use of language, which
does not have communicative intent. If there is adequate
language ability, there is lack of interest in initiating or
sustaining conversation. Play is impaired. Spontaneous
imaginative play and social imitative play appropriate for
developmental level is absent or substantially delayed.
Restr ic ted interests and act iv i t ies involve usual ly an
encompassing preoccupation with one or several topics, which
may be abnormal in focus, intensity or both (e.g. train
schedules; prime numbers; laundry detergents etc). Disabling
adherence to non-functional routines is also common.
Stereotyped movements and mannerisms such as hand
flapping, body rocking, staring, is present.
Autism and the related PDDs are one of the leading cau-
ses for developmental disability. Over 300,000 individuals
in the US have been diagnosed with autism spectrum
disorder.
3
 The condi t ion has ser ious soc io -economic
consequences, because it begins in childhood, it is chronic,
and the disability can be substantial. The costs to society
are significant in terms of special educational programs,
suppor t  serv ices,  res ident ia l  inst i tut ions and loss of
productivity for the affected individuals, but also family
members. The financial, and more importantly, emotional
burden to the parents and families of affected children, can
also be substantial. There are no established definitive
treatments, but there is a plethora of treatments with limited
at best empirical support or “alternative treatments” with no
scientific evidence at all. The disabling nature of the disorder
and the lack of sufficiently effective treatments continue to
st i r  keen publ ic interest,  sometimes propel l ing novel
unproven t rea tments  to  ins tan t  fame and pub l i c i t y.
Unfortunately the initial enthusiasm often leads to the
disappointment of many hopeful and dedicated patients.
Typically, first line treatment for children with autism include
psychosocial treatments and educational interventions with
the goal of maximizing language acquisition, improving social
and communication skills and extinguishing of maladaptive
behaviors. Currently there are no available standard medication
treatments, addressing the core symptoms of autism. There
are no pharmacological treatments currently approved by the
US Food and Drug Administration for autism. Despite the
limited empirical support psychopharmacological treatment of
children and adults with autism appears to be common in
clinical practice. When used, pharmacologic interventions
usually target specific symptoms, accompanying the core
symptoms, and severely impairing the individual’s functioning,
often not allowing for “first line” educational and behavioral
interventions to take pace (e.g. aggression, self-injurious
behavior; compulsive rituals, low frustration tolerance with
explosive outbursts, hyperactivity etc.). The agents used
commonly in clinical practice belong to diverse medication
groups, are non-specific to the symptoms targeted, and affect
a wide range of neurological and brain functions, not affected
necessarily by autism. Although medications may improve the
quality of life for some patients, medication benefits maybe
narrow in scope. Moreover, available data make it difficult to
predict which patients will respond positively to which
medication. Finally long term benefits for any of the agents
used in autism are largely unknown and a significant portion
of patients discontinue once perceived beneficial medication
use due to loss of efficacy or side effects. Studies are under
way now to determine the utility of longer term use of some of
the more popular agents.
The current research in the area of pharmacological
treatments for autism borrows treatments from psychiatric
conditions for symptoms that might be relevant for autism.
The newer psychotropics, part icular ly the atypical
antipsychotics and the selective serotonin reuptake inhibitors
(SSRIs) have more benign side effect profiles than older
counterpar ts.  There is urgent need, however,  for the
development of new agents, specific to autism, and possibly
attacking core symptoms of the disease. The hope is that the
advances in knowledge of the biological substrates for autism
will lead to the development of new such compounds.
Existing treatments
This section will provide an overview of the major drug
categories commonly used in the treatment of children and
adults with autism and related conditions.
Atypical antipsychotics (AAPs), are a group of drugs originally
developed to treat psychosis. The group includes compounds
brought to the market over the past 10 years as safer and
better  to lerated al ternat ives to the exist ing “ typical”
antipsychotics. Medications in this group include clozapine,
r isper idone, olanzapine, quet iapine, z iprazidone and
aripiprazole. These compounds are widely used in autism and
other PDDs to treat severe maladaptive behaviors and have
largely replaced the traditional (typical) antipsychotics such
as haloperidol and chlorpromazine. The target symptoms for
pharmacotherapy with AAP typically include aggression, self-
injury, property destruction or severe tantrums. The impetus
for studying these agents in PDDs was derived largely by
research on haloperidol, done by Magda Campbell’s group in
New York.
4
 The AAPs, however offer distinct advantages over
the typical antipsychotics represented by haloperidol. The AAPs
have lower risk of inducing neurological side effects such as
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Parkinsonism in the short term and perhaps tardive dyskinesia
(TD) in the long term. In addition, because these newer
compounds have been also reported to improve the “negative”
symptoms of schizophrenia (abulia, avolia, flat affect), there
is interest in the notion that this may be relevant to the social
withdrawal and lack of spontaneous interaction in autism.
The fact that AAPs are also effective for treatment of tics
5
 with
a similar magnitude of effect as the high potency typical
antipsychotics, also suggests that the AAPs may be of benefit
in the treatment of stereotypies associated with PDDs as well.
The reduced occurrence of dyskinesias and the purported
improvement in negative symptoms of schizophrenia may be
related to the dual action of five-hydroxytryptamine (5-HT) to
dopamine (DA) receptor blockade.
6
 Alternatively, it has been
suggested that the AAPs do not bind as tightly to post-synaptic
dopamine receptors, permitting them to be displaced by
endogenous dopamine in the striatum.
7
 To date clozapine,
r isper idone, olanzapine, quet iapine, z iprazidone and
aripiprazole, have each been examined in the treatment of
autism and other  PDDs albeit with varying levels of empirical
support. Recent data suggest that risperidone is emerging as
the standard treatment for aggression, tantrums, and self-injury
in children, adolescents and adults with PDDs.
1. Clozapine
Clozapine was the first atypical antipsychotic to be introduced
in the US. The drug’s ability to block 5-HT2A, 5-HT2C, 5-HT3
and DA D1-D4 receptors has been proposed as its mechanism of
action. Two reports have described the use of clozapine in autism
in four subjects. In the first study, three children who displayed
marked hyperactivity, fidgetiness, or aggression were treated for
up to 8 months with doses ranging from 200 to 450 mg per day.
Two of the three children showed sustained improvement, though
the third had a return of symptoms to baseline levels after an
initial response. Chen et al. 2001 reported the case of a 17-
year-old male with autism and severe mental retardation who
showed significant reduction in signs of “overt tension”,
hyperactivity, and repetitive motions in response to clozapine 275
mg per day, during a 15-day hospitalization.
8
 These case studies
provided limited support for the use of clozapine.
The low use of clozapine in autism probably reflects concerns
about the risk of blood dyskrasia and seizures that are associated
with the drug. Additionally frequent blood draws (weekly) are
required to monitor for agranulocytosis, which can be
challenging in children with autism.
2. Risperidone
Risperidone has high affinities for DA D2-D4, 5HT2A,
5-HT2C receptors.
9
 Multiple open label studies and case series,
as well as double blind placebo controlled trials in children,
adolescents and adults have described beneficial effects of
risperidone in individuals with autism and other PDDs. The
Research Units in Pediatric Psychopharmacology (RUPP)
Autism Network recently completed a multi-site trial evaluating
the short- and long-term efficacy of risperidone in children
and adolescents with autism accompanied by severe tantrums,
aggression and/or self-injurious behavior.
10
 The first phase of
the study was an eight week randomized double blind trial of
risperidone versus placebo. The second phase was a 4-month-
open-label extension for all subjects who showed a positive
response. The benefits of risperidone were remarkably stable
without the need for dose increase. In a third phase subjects
were randomly assigned to continue active medication or to a
gradual withdrawal to placebo over a 3-week period. The third
phase was terminated after it became clear through interim
analysis that the relapse rate is significantly greater in the
placebo group. The primary outcome measures were the
Irritability subscale of the Aberrant Behavior Checklist (ABC)
(Table 1) and the Improvement item of the Clinical Global
Impression scale (CGI-I) (Figure 1).
The large magnitude of treatment effect found (43%
difference in the mean change for the main outcome measure
between risperidone and placebo) contrasts to treatment effects
for haloperidol (differences of 15%-20% in similar studies).
4
In addition, the side effects associated with risperidone were
less than those with haloperidol in previous studies. Although
there was significant improvement in hyperactivity and
stereotypies, there was little evidence of benefit for core features
of autism in the short term. Secondary analyses on long-term
effects on adaptive function are ongoing.
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3. Olanzapine
Olanzapine has high affinity for DA D1, D2 and D4 receptors,
for 5-HT2A, 5-HT2C and 5-HT3 receptors.
11
 It has not been
studied in a placebo-controlled randomized fashion in children
or adults with PDD. Several case studies have reported positive
results;
12-13
 one open label trial
14
 and one randomized parallel
group design trial with haloperidol
15
 reported generally positive
results, though significant weight gain did occur. Recent
reports of drug-induced diabetes in adults treated with
olanzapine
16
 may make clinicians reluctant to continue using
it in autism.
4. Quetiapine
Quetiapine has a relatively low to moderate affinity for D1
and D2 receptors, moderate affinity for 5HT2A receptors, and
higher  a f f in i ty  fo r  a lpha1-adrenerg ic ,  H1-his taminic
receptors.
17
 One open label trial with a small number of
subjects, concluded that quetiapine was poorly tolerated and
ineffective in their sample.
18
5. Ziprazidone
Ziprazidone is a potent antagonist of 5-HT2A and D2
receptors, though it has relatively greater affinity for 5-HT2A
receptors. Unlike quetiapine, it has low affinity for adrenergic
and histaminergic receptors.
19
 One open label study and one
retrospective chart review study have shown some promise for
its usefulness in PDD.
20-21
 Double blind placebo controlled
studies are needed to substantiate these findings.
6. Aripiprazole
Aripiprazole is the most recent addition to the list of
available AAPs. It is classified as a partial dopamine agonist
due to a novel mechanism of action.
22
 It has the capacity to
bind with presynaptic dopamine receptors (D2 and D3) and
serotonin 5HT1A, acting as partial agonist, and to 5HT2A
acting as antagonist. It also binds to alpha1A, muscarinic
and histaminergic receptors with minimal antagonism.
Studies in adults with schizophrenia have shown it to be
an effective antipsychotic with a low risk of side effects and
causing no weight gain.
23
 One open-label tr ial with 5
patients 5-18 years-old diagnosed with PDD reported
improvement in maladaptive behavior associated with PDD
in all 5 subjects.
24
 The subjects received aripiprazole for a
minimum of 8 weeks and response was determined by a
Clinical Global Impressions-Improvement (CGI-I) scale rating
of “much improved” or “very much improved”.
More pi lot studies of ar ipiprazole are under way at
several sites.
Serotonin reuptake inhibitors (SRIs)
Serotonin reuptake inhibitors (SRIs) such as clomipramine,
fluoxetine, fluvoxamine, sertraline, paroxetine, citalopram and
escitalopram are a group of chemically unrelated compounds
that potent ly inhibi t  the reuptake of  serotonin (5-
hydroxytryptamine or 5-HT) at the presynaptic transporter site.
Clomipramine is a tricyclic antidepressant (TCA) that inhibits
the reuptake of both norepinephrine and serotonin. The other
compounds are more selective for serotonin reuptake and are
collectively termed selective serotonin reuptake inhibitors
(SSRI). Although commonly used in clinical practice, the SRIs
have not been systematically studied in the PDDs.
SSRIs in PDD
1. Clomipramine
Two studies with crossover design (with desipramine) provided
some evidence that clomipramine may be superior to
desipramine in reducing repetitive behaviors and stereotypies.
25
One subject treated with clomipramine had a seizure; other
adverse effects of clomiptamine included prolonged QTc interval
(ECG change) in one subject and tachycardia in another. Open
label studies of clomipramine, including both children and
adults, reported beneficial effects in mixed populations of PDD
patients.
26-28
 One study showed generally poor response to
clomipramine.
29
 Adverse effects including urinary retention,
drowsiness, aggressive behavior and mood instability were
common. Concerns about lowered seizure threshold in this
seizure-prone population, the need for electrocardiographic
and blood level monitoring, and the inconsistent evidence of
benef i t ,  have made many cl inic ians re luctant to use
clomipramine in children with PDD.
2. Fluoxetine
One recent placebo controlled crossover trial examined the
effects of liquid fluoxetine on repetitive behaviors in 45
children and adolescents diagnosed with PDDs.
30
 The
outcome measures included measures of repetitive behavior
and global improvement. Liquid fluoxetine in small doses
was found more effective than placebo in treating repetitive
behaviors with effects size in the moderate to large range.
Fluoxetine effect did not separate significantly from placebo
on the global improvement measure. Liquid fluoxetine did
not significantly differ from placebo on treatment emergent
side effects. One open label study has also shown indications
of potential benefit from fluoxetine in the treatment of repetitive
behaviors in autism.
31
 Of note responders tended to be in the
lower age group (less than 15). The study noted a high
frequency of activation characterized by hyperactivity,
insomnia and irritability.
3. Fluvoxamine
Fluvoxamine was helpful for compulsive behavior and
aggression as well as increased prosocial behavior, in adults
with autism, who participated in a double-blind placebo
controlled study.
32
 A similar study in children however showed
negative results with side effects of behavior activation
(hyperactivity, disinhibition, insomnia and aggression) in 12
out of 16 subjects.* Another open label study in children with
PDD and anxiety or OCD, in which lower daily doses were
used, showed no statistically significant benefit for the study
group as a whole, but 8 out of 14 subjects showed “a positive
response” (33). Activation leading to discontinuation occurred
in only 3 subjects, suggesting that activation is dose related.
4. Sertraline
No controlled studies on sertraline in subjects with autism
have been published. Several open label studies have
demonstrated benefits for aggression, repetitive and self-
injurious behavior in adults with PDD.
34-35
 In a case series
36
eight out of nine children with autism, sertraline showed
significant improvement in anxiety, irritability and ability to
manage transitions. Two exhibited agitation when the dose
was raised to 75 mg/d.
* McDougle, unpublished 2002
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5. Paroxetine
No controlled studies have been published with paroxetine
in the treatment of individuals with autism. Two single case
reports described decreased self-injurious behavior in one case,
and reduct ion in i r r i tabi l i ty,  temper tantrums and
preoccupations in another.
37-38
 An open label study of adults
with mental retardation, some of them with PDD, described
effectiveness of paroxetine for treatment of aggression at one
month, but not at 4 month follow up.
39
6. Citalopram and escitalopram
One retrospective review of the medical charts of 15 children
and adolescents diagnosed with PDDs assessed the effectiveness
and tolerability of treatment with citalopram.
40
 Anxiety and mood
symptoms, as well as PDD symptoms, were found significantly
improved on a clinician rated global improvement measure.
Five of the patients (33%) reported “mild side effects”. No
studies on the use of escitalopram for treatment of PDDs have
been published yet in the US. A federally funded multisite
study of citalopram in children with PDD targeting repetitive
behavior is currently under way in the US.
7. Mirtazepine
Mirtazepine is an atypical antidepressant in that it possesses
both serotoninergic and adrenergic activity. An open label trial
treating 26 children with autism reported modest efficacy for
symptoms including aggression, self-injur y, irr i tabil i ty,
hyperactivity, anxiety, depression and insomnia. Adverse effects
were minimal and included increased appetite, irritability and
transient sedation.
41
In summary, the available evidence provides only limited
support for the use of SRIs in children with PDD. The studies
conducted have been small in sample sizes and with poorly
described target symptoms. Support for the use of these
compounds for treatment of repetitive behaviors in children,
adolescents and adults with PDD is stronger. Generally safe in
short-term trials, these agents seem more likely to cause behavior
activation in children, and more commonly in younger children.
St imulants
The stimulant medications (methylphenidate, d-amphetamine,
and d,l-amphetamine) are a well established treatment for
Attention Deficit Hyperactivity Disorder (ADHD) in typically
developing children. Strong evidence for the long term benefits
of well managed stimulant medication was provided by a recent
large multicenter trial sponsored by the National Institute for
Mental Health (NIMH).
42
 Motor restlessness, hyperactivity,
distractibility and disruptive behavior are common symptoms
in children with PDDs. The use of stimulants in the population
of children with PDD and hyperactivity has been the focus of
recent interest (Table 2).
Community and clinic-based surveys indicate that the
stimulants are commonly used in children with PDD. Published
data suggest that stimulant medication can be effective in
children with developmental disabilities and ADHD symptoms.
However children with developmental disabilities and ADHD
are at higher risk of adverse effects from stimulant treatment
than typically developing children with ADHD. Also the rate of
responders and the mean percentage of improvement are
somewhat lower. Preliminary results from the RUPP Autism
Network are consistent with these general conclusions. In
the RUPP study, 66 children participated in a crossover study
involving three dose levels of methylphenidate and placebo.
Miscellaneous compounds
1. Mood stabilizers
Anticonvulsants are commonly used in clinical practice in
the treatment of autistic children and adults. This has to do
partly with the high incidence of seizure disorder in autistic
individuals. However this class of compounds has been also
evaluated in several case studies and small open-label studies
in the treatment of aggression and behavior dyscontrol
associated with autism. Single cases have been reported on
the use of lithium carbonate in the treatment of refractory
aggression in adults with autism.
43-44
 A retrospective case series
of divalproex sodium use in the treatment of children and
adults with autism reported favorable changes in instability,
repetitive behaviors and aggression.
45
 A study of lamotrigine
in 28 children with autism showed no separation between
active drug and placebo on measures of stereotypies, lethargy,
irritability, hyperactivity, emotional reciprocity, sharing pleasures
and in language and communication, socialization, and daily
living skills noted after 12 weeks.
46
 Concern about adverse
skin reactions in children – skin rash and Steven-Johnson
Syndrome – cause many clinicians to be reluctant about the
use of this drug in children.
47
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2. Naltrexone
Naloxone and naltrexone are opiate antagonists that have
been evaluated in autism. Naloxone is short-acting and has to
be administered parenterally. This limits its clinical applications.
The plasma half-life of orally administered naltrexone is between
4 and 10 hours. The use of these compounds in autism is
based on the putative role of endogenous opioids such as beta-
endorphin and encephalins in the regulation of social behavior.
Results from animal studies suggest that opioids may play a
role in maternal-infant attachment by influencing feelings of
social comfort and reducing separation distress reactions. Initial
reports of open-label studies with naltrexone in autism seemed
promising,
48-49
 but results of subsequent placebo-controlled
studies were disappointing. Modest benefits were observed in
hyperactivity,
50-51
 but no positive effects for language function
or communication.
52
 Common side effects were sedation and
decreased appetite.
3. Secretin
There was much initial excitement concerning the use of the
gastrointestinal peptide secretin in the treatment of autism.
53
 A
series of randomized, double-blind, placebo-controlled trials of
intravenous infusion of the agent followed. Indeed, secretin is
the best-studied drug for treatment of autism, involving nearly
600 children. The results of these studies are remarkably
consistent showing no evidence of efficacy for secretin in autism.
Altogether nearly 500 children with autism or PDD have
been studied during randomized clinical trials of secretin. Thus
although it is perhaps the best-studied treatment for autism,
secretin is not effective (Table 3).
Glutaminergic function has been recently researched
vigorously and is considered to be affected in a number of
neuropsychiatric disorders.
57
 Parallels are drawn between
schizophrenia, which is considered a hypoglutamatergic
disorder and autism, which also has been suggested to
represent a hypoglutamatergic disorder.
58
 Negative symptoms
of schizophrenia, including social withdrawal, resemble
behaviors characteristic of autistic disorder, and are thought
to be related to glutaminergic receptor function. 5-HT2A
antagonist and Glutamate agonist have been proposed as
potential therapy for autism.
58
 One compound of interest is D-
cycloserine (DCS) a partial agonist of the strychnine-insensitive
glycine recognition site or glycineB-site on the NMDA recep-
tor complex. Originally DCS was used to treat tuberculosis
with a mild side effect profile. Largely because full glycineB
agonists (e.g. glycine, d-serine) often produce serious side-
effects like neurotoxicity, DCS and other partial agonists are
receiving more and more attention for their modulatory effects
at the NMDA receptor complex. At low doses (50 mg/d or <
20 mg/kg) DCS has an agonistic profile, but at higher doses it
can displace agonists with higher intrinsic activity and show
an antagonistic profile, such as anticonvulsive activity.
Based on the glutamatergic receptor hypofunction hypothesis
and the fact that DCS has, at least at lower doses, a facilitatory
effect at the NMDA receptor, there might be a role for DCS in
autism. DCS has been shown to facilitate learning and memory
recovery. This was experimented through fear extinction
measured with potentiated startle in rats.
59
 Recently the findings
of potential benefit for DCS as an addition to antipsychotics in
the treatment of schizophrenia were substantiated in an fMRI
study, which found that the beneficial effect of DCS on negative
symptoms of schizophrenia was associated with enhanced
temporal lobe function.
60
 An open label pilot-study with DCS
in humans with Autistic Disorder found an association with
reduced social withdrawal and increased social responsiveness
as measured on the social withdrawal subscale of the ABC.
61
Only at the highest dose some adverse effects were reported.
In combination the above mentioned effects in schizophrenia
and the positive preliminary findings of Posey et al. suggest
DCS as a possible treatment option for autism, as mono- or
adjunct therapy. Larger double-blind placebo-controlled
randomized clinical trials seem warranted.
Amantadine hydrochlor ide is another g lutaminergic
compound acting as a noncompetitive antagonist at the NMDA
receptor. King et al 2001 examined the effects of amantadine
in a double-blind placebo-controlled trial involving 39
individuals with autistic disorder.
62
 There was no statistically
significant difference in parent rated measures of irritability
and hyperactivity between amantadine and placebo. Clinician-
rated measures of hyperactivity and inappropriate speech
showed statistically significant improvement in the amantadine
group. The drug was well tolerated.
 Conclusion
Advances in the pharmacological treatment of autistic disorder
have followed biological research in that area since it began
in the 1950s and have been modest. Only a limited number
of randomized, placebo-controlled studies have been published.
Recent action of the US NIMH to fund the RUPP autism
network has resulted in completion of the largest controlled
therapeutic trial in autistic disorder to date. Although with
disappointing results, the recent series of secretin studies
demonstrate improved capacity in the field to carry out rigorous
Several promising new directions have originated in the
research of drugs for autism. Neuroimmune therapies are
based on proposed viral and autoimmune mechanisms in
the aetiology of autism. An extensive body of literature
regarding immune abnormalities in autistic disorder has been
published.
54
 Only limited number of treatment studies have
been conducted in this area. DelGuidice-Asch reported that
open label, intravenous immunoglobulin was of only limited
benefit in a minority of subjects, if at all.
55
 Sandler et al.
reported a 8-week open label trial of the antibiotic vancomycin
in 10 children with “regressive” onset autistic disorder,
fo l lowing antecedent  broad-spect rum ant imicrobia l
exposure.
56
 Eight of the ten children were noted to show
improvement in communication and behavior during the
study, with return to baseline upon drug discontinuation.
The authors concluded that there is possible gut flora – brain
connection, which warrants further investigation. Controlled
studies of drugs having direct effect on immune function
have not been conducted in autistic disorder.
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clinical trials examining efficacy and safety. Future research
is likely to include additional trials of antipsychotics in
individuals with autistic disorder and PDD. Assessment of long-
term safety and efficacy is needed with all therapeutic agents.
Larger controlled studies of stimulants and SRIs have been
already undertaken and are likely to inform further clinical
pract ice. New compounds, based on advances in
understanding the pathophysiological underpinnings of the
disorder, are also likely to emerge. Trials looking at the
combinat ion and sequencing of pharmacological  and
behavioral treatments are needed and have been launched by
the RUPP Autism Network.
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